Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1173-1184

  Zhang, Qingbei ^a   Bindokas, Vytas ^a   Shen, Jikun ^a   Fan, Hanli ^a   Hoffman, Robert M ^b,c   Xing, H Rosie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b ANTICANCER INC   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PACLITAXEL; RAPAMYCIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL REACTIVITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; FLUORESCENCE IMAGING; FLUORESCENCE MEDIATED TOMOGRAPHY; GIANT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOMOGRAPHY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960134214     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0008     Document Type: Article

References (35)

1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
2. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-95. (Pubitemid 46160619)
3. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70. (Pubitemid 26419043)
4. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95:4607-12. (Pubitemid 28207960)
5. Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics->mechanism(s) of interaction). Cancer Metastasis Rev 1996;15:247-72.
6. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
7. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6. (Pubitemid 38697278)
8. Kadambi A, Mouta Carreira C, Yun CO, Padera TP, Dolmans DE, Carmeliet P, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001;61:2404-8. (Pubitemid 32685814)
9. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52. (Pubitemid 38821812)
10. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979-86. (Pubitemid 36829677)
11. Winkler F, Kozin SV, Tong RT, Chae S, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63. (Pubitemid 40017699)
12. Li X, Wang J, An Z, Yang M, Baranov E, Jiang P, et al. Optically imageable metastatic model of human breast cancer. Clin Exp Metastasis 2002;19:347-50.
13. Gupta VK, Jaskowiak NT, Beckett MA, Mauceri H, Grunstein J, Johnson R, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002;8:47-54.
14. Cao Q, Li ZB, Chen K, Wu Z, He L, Neamati N, et al. Evaluation of biodistribution and antitumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging 2008;35:1489-98.
15. Volk LD, Flister MJ, Bivens CM, Stutaman A, Desai N, Trieu V, et al. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent antivascular endothelial growth factor A therapy. Neoplasia 2008;10:613-23. (Pubitemid 351770305)
16. Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H, et al. Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res 2006;66:4208-14.
17. Zhang Q, Yang M, Shen J, Gerhold LM, Hoffman RM, Xing HR. The role of the intravascular microenvironment in spontaneous metastasis development. Int J Cancer 2010;126:2534-41.
18. Montet X, Figueiredo JL, Alencar H, Ntziachristos V, Mahmood U, Weissleder R. Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 2007;242:751-8.
19. Zhang Q, Fan H, Shen J, Hoffman RM, Xing HR. Human breast cancer cell lines coexpress neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. PLoS One 2010;5:e9712.
20. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-40. (Pubitemid 32769088)
21. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-6. (Pubitemid 36025239)
22. Hanyu A, Kojima K, Hatake K, Nomura K, Murayama H, Ishikawa Y, et al. Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of antihuman VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells. Cancer Sci 2009;100:2085-92.
23. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15:1612-22.
24. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729-35. (Pubitemid 46548961)
25. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-5. (Pubitemid 30636613)
26. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9. (Pubitemid 32937367)
27. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008;14:382-93.
28. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000. (Pubitemid 34224587)
29. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008;456:809-13.
30. Jain RK, Munn LL, Fukumura D. Dissecting tumor pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2:266-76. (Pubitemid 37328780)
31. Baish JW, Netti PA, Jain RK. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 1997;53:128-41. (Pubitemid 27202429)
32. Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anti-Cancer Drugs 2010;21:687-94.
33. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Res 2003;63:5521-5. (Pubitemid 37139872)
34. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003;113:151-60. (Pubitemid 36999806)
35. Amoh Y, Li L, Yang M, Moossa AR, Katsouka K, Penman S, et al. Nascent blood vessels in the skin arise from nestin-expressing hairfollicle cells. Proc Natl Acad Sci U S A 2004;101:13291-5. (Pubitemid 39209658)